Literature DB >> 14976858

Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases.

Antonio Mafrici1, Antonia Alberti, Elena Corrada, Stefano Ferrari, Biondino Marenna.   

Abstract

5-Fluorouracil, a widely used drug in cancer treatment, is known to have cardiotoxic effects: chest pain with ECG changes, arrhythmias, arterial hypertension or hypotension, myocardial infarction, cardiogenic shock and sudden death have been described in the literature. Coronary artery vasospasm is the pathogenetic mechanism hypothesized in most cases, but mechanisms other than myocardial ischemia had been advocated in some patients. The approach to the patient with persistent chest pain, despite therapy and persistent ST-segment elevation mimicking an acute myocardial infarction, has not been well addressed, and the appropriate diagnostic and therapeutic pathways have not yet been defined. We present our experience regarding 2 patients treated with 5-fluorouracil and referred to our coronary care unit because of prolonged chest pain (in one case with clinical evidence of hemodynamic impairment) and persistent ST-segment elevation, in whom an acute myocardial infarction was suspected. One patient was treated with systemic fibrinolysis, and coronary angiography was performed 6 days later; the other was submitted to urgent coronary angiography shortly after admission. In both cases the ECG and echocardiographic abnormalities were transient and normalized within a few days, the serum markers of myocardial necrosis were persistently in the normal range and the coronary artery trees were normal. The diagnostic and therapeutic approach to patients with this unusual clinical presentation is also discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14976858

Source DB:  PubMed          Journal:  Ital Heart J        ISSN: 1129-471X


  5 in total

1.  Primary percutaneous coronary intervention and intravascular ultrasound imaging for coronary thrombosis after cisplatin-based chemotherapy.

Authors:  Daisuke Ito; Jun Shiraishi; Takeshi Nakamura; Naoki Maruyama; Yumi Iwamura; Sho Hashimoto; Masayoshi Kimura; Akihiro Matsui; Hirokazu Yokoi; Masayasu Arihara; Hidekazu Irie; Masayuki Hyogo; Takatomo Shima; Yoshio Kohno; Akiyoshi Matsumuro; Takahisa Sawada; Hiroaki Matsubara
Journal:  Heart Vessels       Date:  2012-01-05       Impact factor: 2.037

2.  Acute myocardial infarction in a patient with chronic myelocytic leukemia during chemotherapy with hydroxyurea.

Authors:  H Kälsch; H Wieneke; R Erbel
Journal:  Herz       Date:  2010-09       Impact factor: 1.443

3.  Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study.

Authors:  Merete Vaage-Nilsen; Dorte L Nielsen; Anne Dyhl-Polk; Morten Schou; Kirsten K Vistisen; Anne-Sophie Sillesen; Eva Serup-Hansen; Jens Faber; Tobias W Klausen; Stig E Bojesen
Journal:  Oncologist       Date:  2020-10-07

4.  Aspartate 338 contributes to the cationic specificity and to driver-amino acid coupling in the insect cotransporter KAAT1.

Authors:  S A Mari; A Soragna; M Castagna; E Bossi; A Peres; V F Sacchi
Journal:  Cell Mol Life Sci       Date:  2004-01       Impact factor: 9.261

Review 5.  A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity.

Authors:  Anne Polk; Kirsten Vistisen; Merete Vaage-Nilsen; Dorte L Nielsen
Journal:  BMC Pharmacol Toxicol       Date:  2014-09-04       Impact factor: 2.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.